Medifast (MED) Expected to Release Earnings on Monday

Medifast (NYSE:MED) is expected to report Q3 2025 earnings of ($0.01) per share on $84.10 million in revenue, against company guidance of -0.600-0.00 EPS. This follows a Q2 performance where the company surpassed analyst estimates with $0.04 EPS and $105.56 million in revenue. Institutional investors hold a significant 95.51% stake, with several hedge funds, including Man Group and Bank of America, recently increasing their positions, highlighting continued institutional interest ahead of the anticipated Q3 results.

Analysis

Medifast (NYSE: MED) is anticipated to report Q3 2025 earnings on November 3rd, with analysts forecasting a loss of ($0.01) per share on $84.10 million in revenue, aligning with the company's guidance of -0.600-0.00 EPS. This contrasts sharply with Q2 2025, where MED significantly surpassed expectations, reporting $0.04 EPS against a ($0.22) consensus and $105.56 million in revenue versus $96.10 million estimated. The prior quarter's strong beat, coupled with a 2.00% return on equity and 0.76% net margin, indicates recent operational efficiency.

Despite the anticipated Q3 loss, institutional investors maintain a substantial presence, holding 95.51% of Medifast's stock. Notably, several hedge funds, including Man Group plc and Bank of America Corp DE, increased their stakes by 0.6% and 37.4% respectively in Q2, suggesting continued confidence or strategic positioning. Analysts project a rebound, forecasting $1 EPS for the current fiscal year and $2 EPS for the next, implying a positive longer-term outlook.

Medifast's stock currently trades at $12.06, with a market capitalization of $132.48 million and a P/E ratio of 37.67. The stock's beta of 0.85 indicates lower volatility relative to the broader market. Its current price is near its 1-year low of $11.57, significantly below its 1-year high of $21.98, potentially reflecting market concerns about near-term profitability despite institutional interest.

Key Decisions for Investors

• Investors should closely monitor Medifast's Q3 2025 earnings report for any deviation from the anticipated ($0.01) EPS and $84.10 million revenue, as this will clarify the near-term operational trajectory following a strong Q2 beat.
• Evaluate the implications of significant institutional ownership (95.51%) and recent hedge fund inflows, which suggest a belief in the company's long-term value despite projected near-term losses.
• Consider the stock's current trading near its 1-year low and the analyst's projected full-year EPS of $1 and $2 for the next fiscal year, assessing if the current valuation at a 37.67 P/E ratio presents a buying opportunity or reflects ongoing market skepticism.